Apraglutide SPPS and RP-HPLC Purification for High Purity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing GLP-2 analogs, such as teduglutide, have short half-lives and are not suitable for commercial manufacturing due to low purity and impurities, necessitating a high-yielding and substantially pure GLP-2 analog with improved pharmacokinetic properties for treating intestinal disorders like short bowel syndrome.
Innovation Solution
A novel synthesis method involving solid phase peptide synthesis (SPPS), trifluoroacetic acid deprotection, and multiple purifications using reversed-phase high performance liquid chromatography (RP-HPLC) to produce a GLP-2 analog, apraglutide, with purities of at least 95% and specific impurity levels, and a sodium salt formulation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If existing GLP-2 analogs are used for treatment, then intestinal adaptation can be enhanced, but the half-life is short and dosing frequency must be high
Solution Approach 1:
The patent applies parameter changes by modifying the amino acid sequence of GLP-2 analogs through specific substitutions (e.g., position 25 substitutions with hydrophobic amino acids like norleucine, phenylalanine, or tryptophan) to alter pharmacokinetic properties. These structural parameter changes extend the half-life from minutes to hours, enabling less frequent dosing while maintaining therapeutic efficacy for intestinal adaptation
2Manufacturing precision
If conventional synthesis methods are used for GLP-2 analogs, then production can be achieved, but purity is low and impurities are high
Solution Approach 1:
The patent employs preliminary action through optimized solid-phase peptide synthesis (SPPS) protocols that incorporate pre-planned purification strategies. The synthesis method includes specific cleavage conditions (TFA-based cocktails with scavengers) and sequential purification steps (reverse-phase HPLC, preparative HPLC) designed in advance to remove impurities before they become problematic, achieving ≥95% purity
Solution Approach 2:
The patent applies extraction principles by using reverse-phase high-performance liquid chromatography (HPLC) to separate and remove impurities from the synthesized GLP-2 analogs. The purification process extracts unwanted byproducts, degradation products, and incomplete sequences, leaving only the high-purity active pharmaceutical ingredient
3Duration of action of moving object
If GLP-2 analogs with extended half-lives are synthesized, then pharmacokinetic properties are improved, but manufacturing complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the complex synthesis and purification process into distinct modular stages: (1) solid-phase peptide synthesis with specific amino acid coupling, (2) TFA-mediated cleavage and deprotection, (3) initial purification by reverse-phase HPLC, and (4) final polishing by preparative HPLC. This segmented approach manages complexity while achieving the desired extended half-life through structured amino acid modifications
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method achieves high purity apraglutide with improved pharmacokinetic properties, enabling less frequent dosing and effective treatment of intestinal disorders by enhancing intestinal adaptation and reducing parenteral support requirements.
Implementation Method 1
performing two purifications using reversed-phase high performance liquid chromatography (RP-HPLC)
Implementation Method 2
deprotecting the side chains of the peptide by treating the resin with a solution comprising trifluoroacetic acid (TFA), water, and anisole
Implementation Method 3
freeze-drying and packaging the purified peptide powder comprising the substantially pure GLP-2 analog peptide
Data Source
AI summary
The present disclosure relates to methods of making, formulating and administering GLP-2 analogs.